FutureFemHealth

FutureFemHealth

Home
Work with us / Advertise
CensHERship
FutureFemHealth Pro
Partners and contributors
Archive
About
💌 Issue 160: $30m for heavy menstrual bleeding | Rael PE investment | $284m period care deal | HPV home testing
+ lots more in the weekly briefing on the global women's health market
 • Anna O'Sullivan
Reimbursement has moved up the women’s health agenda. Here’s why.
Founders and investors are thinking about who pays much earlier.
 • Anna O'Sullivan
Women’s health companies urged to weigh in on US Medicare payment changes
Advocates say the industry needs to make its voice heard
 • Anna O'Sullivan
Channel Medsystems raises $30m to expand heavy menstrual bleeding treatment
US medtech will accelerate commercial rollout of its non-hormonal Cerene treatment
 • Anna O'Sullivan
💌 Issue 159: $275m osteoporosis bet | FemTech & the NHS | New menopause drug data | Fertility reimbursement
+ lots more in the weekly briefing on the global women's health market
 • Anna O'Sullivan
Largest study to date maps how female testosterone levels change with age
Findings show testosterone declines gradually with age - rather than dropping off around menopause
 • Anna O'Sullivan
Is getting FemTech into the NHS solely an NHS problem?
A new Parliamentary briefing puts some of the responsibility back on the sector
 • Anna O'Sullivan
What happened to the women’s health market for women 65+?
Few companies have built specifically for older women. But that doesn't mean the market isn't emerging.
 • Anna O'Sullivan
💌 Issue 158: Clair Health + Mayo Clinic | $58M women’s health fund | HRT use doubles
+ lots more in the weekly briefing on the global women's health market
 • Anna O'Sullivan
The Women's Health Innovation Map: Why ecosystems matter beyond capital
A companion read to the Women's Health Innovation Map, curated by Anastasiya Markvarde.
 • Anna O'Sullivan and Anastasiya Markvarde
Clair Health joins Mayo Clinic programme to build clinical evidence behind hormone wearable
After attracting attention - and debate - for its approach to continuous hormone monitoring, Clair is embarking on a multi-year clinical validation…
 • Anna O'Sullivan
💌 Issue 157: Oura + Maven fertility study | $200M Yarrow deal | Pregnancy hypertension up 73%
+ lots more in the weekly briefing on the global women's health market
 • Anna O'Sullivan
© 2026 FutureFemHealth Ltd · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture